Additionally, XRCC2 was also lowly expressed in ovarian cancer tissues, and indicated a better survival for ovarian malignance patients, However, in stage I and II ovarian carcinoma, the high XRCC2 expression was linked with a poorer PFS, which may be due to the different role of XRCC2 gene in early stage and late stage. This evidence concerns the gene XRCC2 and ovarian carcinoma.